The Drug Pricing Summit Pharma Wasn't Invited To

Does the Trump-Cummings confab mean that drug makers are doomed to price negotiations in Medicare Part D? (Answer: Almost certainly not, but this is Trump we're talking about.)

The loudest health care news of the day in Washington on March 8 was the parliamentary theater in the two House committees marking up the Republican legislation to repeal and replace Obamacare. The most significant event for the pharmaceutical industry, however, occurred a few blocks down Pennsylvania Ave. and wasn't webcast.

President Trump met at the White House with Reps. Elijah Cummings, D-Md., and Peter Welch, D-Vt

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

More from Market Access